We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) and its Japan-based partner Daiichi Sankyo announced that the FDA has granted approval to its breast cancer drug, Enhertu (trastuzumab deruxtecan) for the second indication — HER2-positive metastatic gastric cancer. The approval is for patients who have received a prior trastuzumab-based regimen.
The approval was based on positive results from the randomized DESTINY-Gastric01 phase II study. Data from the study showed that treatment with Enhertu, an antibody drug conjugate, led to a statistically significant and clinically meaningful improvement in overall survival (OS) and objective response rate (ORR) versus chemotherapy in patients with metastatic HER2-positive gastric cancer with progression following first-line treatment. With the approval, Enhertu becomes the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Following the U.S. approval for the gastric cancer indication, AstraZeneca is due to make a milestone payment of $115 million to Daiichi Sankyo.
The FDA had earlier granted Enhertu Breakthrough Therapy Designation (BTD) in HER2-positive metastatic gastric cancer and Orphan Drug Designation for gastric cancer.
In the past six months, AstraZeneca’s shares have lost 12.5% against an increase of 3.7% for the industry.
AstraZeneca had acquired joint development and commercialization rights to trastuzumab deruxtecan from Daiichi in April 2019. Trastuzumab deruxtecan was approved by the FDA in third-line HER2-positive metastatic breast cancer in December 2019 and immediately launched under the brand name of Enhertu.
Sales of Enhertu in the United States are recognized by Daiichi Sankyo while AstraZeneca records its share of profit from sales of the drug in the United States as collaboration revenues. In the first nine months of 2020, Enhertu generated collaboration revenues of $63 million for AstraZeneca. The collaboration revenues should increase with the FDA approval for the gastric cancer indication.
Enhertu is part of AstraZeneca’s flourishing oncology portfolio. Other key oncology drugs in AstraZeneca’s portfolio areTagrisso, Lynparza and Imfinzi. AstraZeneca markets Lynparza in partnership with Merck (MRK - Free Report) .
Some better-ranked drug/biotech stocks are Novavax (NVAX - Free Report) and Alexion Pharmaceuticals . While Novavax has a Zacks Rank #1 (Strong Buy), Alexion has a Zacks Rank #2 (Buy).
Novavax’s shares have risen 2120.3% in the past one year while its earnings estimate for 2021 have risen 30.7% over the past 60 days.
Alexion’s shares have gained 38.3% in the past one year while its earnings estimates for 2021 have risen 2.9% over the past 90 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
AstraZeneca (AZN - Free Report) and its Japan-based partner Daiichi Sankyo announced that the FDA has granted approval to its breast cancer drug, Enhertu (trastuzumab deruxtecan) for the second indication — HER2-positive metastatic gastric cancer. The approval is for patients who have received a prior trastuzumab-based regimen.
The approval was based on positive results from the randomized DESTINY-Gastric01 phase II study. Data from the study showed that treatment with Enhertu, an antibody drug conjugate, led to a statistically significant and clinically meaningful improvement in overall survival (OS) and objective response rate (ORR) versus chemotherapy in patients with metastatic HER2-positive gastric cancer with progression following first-line treatment. With the approval, Enhertu becomes the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Following the U.S. approval for the gastric cancer indication, AstraZeneca is due to make a milestone payment of $115 million to Daiichi Sankyo.
The FDA had earlier granted Enhertu Breakthrough Therapy Designation (BTD) in HER2-positive metastatic gastric cancer and Orphan Drug Designation for gastric cancer.
In the past six months, AstraZeneca’s shares have lost 12.5% against an increase of 3.7% for the industry.
AstraZeneca had acquired joint development and commercialization rights to trastuzumab deruxtecan from Daiichi in April 2019. Trastuzumab deruxtecan was approved by the FDA in third-line HER2-positive metastatic breast cancer in December 2019 and immediately launched under the brand name of Enhertu.
Sales of Enhertu in the United States are recognized by Daiichi Sankyo while AstraZeneca records its share of profit from sales of the drug in the United States as collaboration revenues. In the first nine months of 2020, Enhertu generated collaboration revenues of $63 million for AstraZeneca. The collaboration revenues should increase with the FDA approval for the gastric cancer indication.
Enhertu is part of AstraZeneca’s flourishing oncology portfolio. Other key oncology drugs in AstraZeneca’s portfolio areTagrisso, Lynparza and Imfinzi. AstraZeneca markets Lynparza in partnership with Merck (MRK - Free Report) .
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked drug/biotech stocks are Novavax (NVAX - Free Report) and Alexion Pharmaceuticals . While Novavax has a Zacks Rank #1 (Strong Buy), Alexion has a Zacks Rank #2 (Buy).
Novavax’s shares have risen 2120.3% in the past one year while its earnings estimate for 2021 have risen 30.7% over the past 60 days.
Alexion’s shares have gained 38.3% in the past one year while its earnings estimates for 2021 have risen 2.9% over the past 90 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>